Related Experiment Videos
Impact of an integrated intervention program on atorvastatin adherence: a randomized controlled trial
Nilesh J Goswami1, Mitch Dekoven, Andreas Kuznik
1Prairie Heart Cardiovascular Consultants, Springfield, IL, USA.
International Journal of General Medicine
|August 13, 2013
Summary
An integrated intervention program, including nurse counseling and copay relief, did not significantly improve atorvastatin adherence in patients. Usual care was as effective as the intervention for atorvastatin adherence.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Health Services Research
Background:
- Patient adherence to statin therapy, such as atorvastatin, is crucial for managing cardiovascular risk.
- Intervention programs aim to improve medication adherence and patient outcomes.
- Previous interventions have shown mixed results in improving adherence to cholesterol-lowering medications.
Purpose of the Study:
- To evaluate the effectiveness of an integrated intervention program on atorvastatin adherence.
- To compare adherence rates between patients receiving the intervention and those receiving usual care.
- To identify factors influencing atorvastatin adherence in a real-world clinical setting.
Main Methods:
- A prospective, randomized interventional study was conducted with patients prescribed atorvastatin.
- The intervention included nurse counseling, copay relief cards, and a monthly newsletter.
- Data were collected from electronic medical records and merged with longitudinal data for analysis.
Main Results:
- The mean 6-month adherence rate was 0.82 in both the intervention and control groups.
- Proportion of days covered and mean persistent days were similar between groups for both new and continuing users.
- The risk of discontinuation of atorvastatin therapy was not significantly different between the intervention and control groups (hazard ratio 0.83, P = 0.55).
Conclusions:
- The integrated intervention program did not significantly improve atorvastatin adherence compared to usual care.
- The findings suggest that the tested intervention may not be effective in enhancing medication adherence in this patient population.
- Further research is needed to explore alternative strategies for improving atorvastatin adherence.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...